Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 10,000 shares at $2.97 ($29K) on 2015-12-14, disclosed to the SEC on 2015-12-16.
Open-market purchase of $29k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.30 | 600 | $1K | 4.7% |
| 2 | $2.89 | 3,000 | $9K | 29.8% |
| 3 | $2.90 | 1,400 | $4K | 14.0% |
| 4 | $2.97 | 1,500 | $4K | 15.3% |
| 5 | $2.98 | 500 | $1K | 5.1% |
| 6 | $3.00 | 3,000 |
| $9K |
| 31.0% |
| Total | $2.91 avg | 10,000 | $29K | 100% |
| Filing → |
| RLMD | BUY | 2024-09-11 | $65K | — | Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |